Lantern Pharma (NASDAQ: LTRN), a biotechnology firm at the forefront of using artificial intelligence to revolutionize oncology drug development, has announced a strategic partnership with IBN to spearhead its corporate communications efforts. This collaboration comes at a pivotal moment as Lantern Pharma advances its AI-guided pipeline, which includes promising therapies for a range of cancers such as lung, brain, breast, and blood cancers. The company’s innovative approach, powered by its RADR(R) AI platform, has significantly reduced the time and cost associated with bringing new cancer treatments from the lab to clinical trials.

The engagement with IBN is aimed at bolstering investor awareness and highlighting the progress Lantern Pharma is making with its precision oncology drugs. Among its pipeline are three AI-guided drug candidates and a subsidiary focused on central nervous system (CNS) cancers, all of which are currently in active clinical trials. The company’s ability to leverage over 200 billion oncology-focused data points and a library of more than 200 machine learning algorithms has positioned it as a leader in the field of AI-driven drug discovery.

Lantern Pharma’s achievements underscore the transformative potential of AI in oncology, offering hope for faster, more cost-effective development of targeted cancer therapies. The partnership with IBN is expected to play a crucial role in communicating these advancements to the investment community and beyond, as the company continues to reach key milestones in its quest to address unmet needs in cancer treatment.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements.